Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Calquence (acalabrutinib) for the Treatment of Mantle Cell Lymphoma

Drug (Brand/Generic)

Calquence/acalabrutinib

Developer

AstraZeneca

Therapy Class

Bruton tyrosine kinase (BTK) inhibitor

Current Indication

Mantle cell lymphoma

Market Sector

Oncology

Development Status

Approved in the US
Expand

Go Top